
SpliceBio
@SpliceBioHQ
Followers
294
Following
149
Media
64
Statuses
160
Genetic medicines company harnessing Protein Splicing to develop the next-gen of gene therapies. Based on technology developed in the Muir Lab at @Princeton.
Barcelona
Joined February 2018
Today @SpliceBioHQ announces a 50M€ Series A to advance our Protein Splicing platform and expand our gene therapy pipeline. Financing co-led by @ucb_news (Ventures) & @YsiosCapital and joined by @NEA, @GildeHealthcare, @Novartis (NVF) and @AsabysPartners.
3
8
46
📽️ Tune in to @CGT_Insights's webinar to hear from our VP of Regulatory Affairs & Quality, Leigh Shaw!. A panel of experts will explore the evolving CGT regulatory landscape with a focus on patient safety. 📅 1 July | 🕓16:00 BST / 17:00 CEST.🔗 Register:
0
0
1
#Stargardtdisease patients currently have no approved treatments for this inherited retinal disorder. Our lead gene therapy, SB-007, is designed to address the underlying genetic cause of the disease with the potential to treat all patients. Discover more:
0
0
1
SpliceBio takes over Times Square! 🗽. Proud to see our $135M Series B milestone spotlighted on the iconic @Nasdaq Tower. Huge thanks to our team & investors powering the next wave of genetic medicines! 💡
0
0
2
RT @PrincetonInnov: The @SpliceBio platform is based on technology developed in @MuirLab at @Princeton.
0
2
0
RT @UKEyeGenetics: Venue at capacity for @UKEyeGenetics annual conference @StAnnesCollege, Oxford!. It is an exciting time to be involved i….
0
4
0
RT @UKEyeGenetics: Enjoying a stimulating day of updates in #ophthalmicgenetics the UK Eye Genetics Group annual conference @StAnnesCollege….
0
1
0
Yesterday, we announced the close of a $135M Series B financing to support clinical development of SB-007 for #StargardtDisease, including the ongoing Phase 1/2 ASTRA and POLARIS studies. Stay tuned as we advance our broader pipeline of genetic medicines.
0
3
5
🌟Financing milestone! #SpliceBio closes $135M Series B to:. 🚀Advance SB-007 for #StargardtDisease.🔬Expand our genetic medicine pipeline. Read more:
0
6
14
We’re proud to join the Community Zoom session hosted by @StargardtsC to share clinical progress on our lead program, SB-007 — the first dual AAV gene therapy in clinical development for #StargardtDisease. 📅 31 May.🕛 12:00–1:30 PM BST. Register here:
0
0
5
May is #HealthyVisionMonth 👁️We are proud to support the #Stargardtdisease community – this March, we dosed the first patient in our Phase 1/2 ASTRA study! Learn more about our mission to address inherited #retinal diseases:
0
0
3
Heading to #ASGCT2025? Connect with #SpliceBio in New Orleans!.Meet CEO Miquel Vila Perello & CBO Gerard Caelles and learn about SB-007 — the first dual AAV #genetherapy in the clinic for #StargardtDisease. The first patient was dosed in the Phase 1/2 ASTRA study in March 2025.
0
1
4
Meet us in Salt Lake City at #ARVO2025!. The #SpliceBio team will be at @ARVOinfo's premier conference for eye & vision specialists from May 4-8. 📅 . Learn about our dual AAV gene therapy for #Stargardtdisease, SB-007, and the Phase 1/2 ASTRA study! 🚀
0
0
2
The #SpliceBio team is heading to Salt Lake City for the Retinal Therapeutics Innovation Summit 2025 on 2 May! Excited to share updates on our dual AAV #genetherapy, SB-007, and connect with leaders in #biotech, #ophthalmology & research. #Stargardtdisease.
0
1
7
Barcelona – A Rising Star in the Life Sciences Industry.In the article ‘Why biotech is booming in Barcelona,’ @NaturePortfolio explores the unique advantages that make Barcelona a hotbed for breakthrough innovation — featuring our very own #SpliceBio here:
0
8
19
Heading to #CGMed25 from📅15–17 April? #SpliceBio will be in Rome for Europe’s premier cell & gene therapy conference!.Let’s connect and discuss our dual AAV #genetherapy, SB-007, for the treatment of Stargardt disease, currently in Phase 1/2 development in the ASTRA study🚀.
0
0
2
📰 Our Co-Founder and CEO is featured in @Bloomberg!.In the latest article, “Big Pharma Is Heading to Barcelona and Here’s Why,” which explores the city’s emergence as a burgeoning biotech hub, Miquel Vila-Perello shares: “I wanted to be part of that.”📍
0
2
6
This #WorldOptometryDay, 23rd March. We at #SpliceBio are proud to be working alongside the #Stargardtdisease patient community to bring a potential treatment option to patients with our dual-AAV gene therapy, SB-007. SB-007 is advancing in the clinic in a Phase 1/2 ASTRA study.
0
0
5
#SpliceBio's CBO, Gerard Caelles to participate in a panel discussion at the @FightBlindness Investing in Cures Summit in Tampa, Florida on 22 March!.Listen in from 14:40-15:20 EDT to learn more about the advancements of genetic medicine strategies to address retinal diseases.
0
0
2